The role of tau protein in HIV-associated neurocognitive disorders

Molecular Neurodegeneration

Brian Giunta³  Jun Tan³  Paul R Sanberg⁴  Adam J Smith⁴  James Scarola²  Lecia AM Brown¹ 

[1] Department of Psychiatry and Behavioral Neurosciences, Neuroimmunology Laboratory, University of South Florida, Morsani College of Medicine, 3515 E. Fletcher Ave., MDT14, Tampa, FL 33613, USA;Department of Molecular Pharmacology and Physiology, University of South Florida, Morsani College of Medicine, Tampa, FL 33613, USA;James A. Haley Veterans Administration Hospital, Tampa, FL 33612, USA;Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida, Morsani College of Medicine, Tampa, FL 33613, USA

关键词: cART;    Inflammation;    Neurodegeneration;    Tau;    Cognitive;    HIV;   

Others  :  1132689
DOI  :  10.1186/1750-1326-9-40

 received in 2014-03-28, accepted in 2014-09-15,  发布年份 2014

【 摘 要 】

Given the increased life expectancy of human immunodeficiency virus (HIV) infected individuals treated with combination antiretroviral therapy (cART) and the ongoing inflammation observed in the brains of these patients, it is likely that premature neurodegeneration as measured by phospho-tau (p-tau) or increased total tau (t-tau) protein may become an increasing problem. This review examines the seven human studies that have occurred over the past 14 years measuring p-tau and/or t-tau in cerebrospinal fluid (CSF) or via post-mortem brain immunohistochemistry. Although not all studies are in agreement as to the changes in p-and t-tau in HIV infected patients, HIV persists in the brain despite cART. Thus is it is suggested that those maintained on long-term cART may develop tau pathology beyond the extent seen in the studies reviewed herein and overtime may then reach the threshold for clinical manifestation.

【 授权许可】

   
2014 Brown et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]AIDS Epidemic Update. Geneva: Joint United Nations Programme on HIV/AIDS and World Health Organization; 2009. http://data.unaids.org/pub/report/2009/jc1700_epi_update_2009_en.pdf webcite, accessed 12 July 2014
• [2]McArthur JC, Steiner J, Sacktor N, Nath A: Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol 2010, 67:699-714.
• [3]Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE: Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007, 69:1789-1799.
• [4]Dunfee R, Thomas ER, Gorry PR, Wang J, Ancuta P, Gabuzda D: Mechanisms of HIV-1 neurotropism. Curr HIV Res 2006, 4:267-278.
• [5]Salemi J, Obregon DF, Cobb A, Reed S, Sadic E, Jin J, Fernandez F, Tan J, Giunta B: Flipping the switches: CD40 and CD45 modulation of microglial activation states in HIV associated dementia (HAD). Mol Neurodegener 2011, 6:3. BioMed Central Full Text
• [6]Petito CK, Cho ES, Lemann W, Navia BA, Price RW: Neuropathology of acquired immunodeficiency syndrome (AIDS): an autopsy review. J Neuropathol Exp Neurol 1986, 45:635-646.
• [7]Ho DD, Rota TR, Schooley RT, Kaplan JC, Allan JD, Groopman JE, Resnick L, Felsenstein D, Andrews CA, Hirsch MS: Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med 1985, 313:1493-1497.
• [8]Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ: The prevalence and incidence of neurocognitive impairment in the HAART era. Aids 2007, 21:1915-1921.
• [9]Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L: HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002, 8:136-142.
• [10]Dreyer EB, Kaiser PK, Offermann JT, Lipton SA: HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. Science 1990, 248:364-367.
• [11]Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006, 12:1365-1371.
• [12]Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, Zaman T, Stone D, Mefford M, Morgello S, Singer EJ, Wolinsky SM, Gabuzda D: Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 2008, 3:e2516.
• [13]Eden A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M: Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis 2007, 196:1779-1783.
• [14]Gartner S, Liu Y: Insights into the role of immune activation in HIV neuropathogenesis. J Neurovirol 2002, 8:69-75.
• [15]Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE: Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol 2005, 64:529-536.
• [16]McGeer PL, McGeer EG: Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol 2002, 8:529-538.
• [17]Perry VH: The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav Immun 2004, 18:407-413.
• [18]Gray F, Chretien F, Vallat-Decouvelaere AV, Scaravilli F: The changing pattern of HIV neuropathology in the HAART era. J Neuropathol Exp Neurol 2003, 62:429-440.
• [19]Gray F, Keohane C: The neuropathology of HIV infection in the era of Highly Active AntiRetroviral Therapy (HAART). Brain Pathol 2003, 13:79-83.
• [20]Cohen RA, Boland R, Paul R, Tashima KT, Schoenbaum EE, Celentano DD, Schuman P, Smith DK, Carpenter CC: Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women. Aids 2001, 15:341-345.
• [21]Kandanearatchi A, Williams B, Everall IP: Assessing the efficacy of highly active antiretroviral therapy in the brain. Brain Pathol 2003, 13:104-110.
• [22]Robertson KR, Robertson WT, Ford S, Watson D, Fiscus S, Harp AG, Hall CD: Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr 2004, 36:562-566.
• [23]Tozzi V, Balestra P, Galgani S, Narciso P, Ferri F, Sebastiani G, D'Amato C, Affricano C, Pigorini F, Pau FM, De Felici A, Benedetto A: Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. Aids 1999, 13:1889-1897.
• [24]Cysique LA, Maruff P, Brew BJ: Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology 2006, 66:1447-1450.
• [25]Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ: Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. Aids 1999, 13:1249-1253.
• [26]Ciccarelli N, Fabbiani M, Di Giambenedetto S, Fanti I, Baldonero E, Bracciale L, Tamburrini E, Cauda R, De Luca A, Silveri MC: Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 2011, 76:1403-1409.
• [27]Liner KJ II, Ro MJ, Robertson KR: HIV, antiretroviral therapies, and the brain. Curr HIV/AIDS Rep 2010, 7:85-91.
• [28]Velasco M, Pareja JA, Losa JE, Valverde JF, Espinosa A, Gujarro C: Dream changes following initiation of efavirenz treatment. Med Clin (Barc) 2011, 136:103-105.
• [29]Del Palacio M, Alvarez S, Munoz-Fernandez MA: HIV-1 infection and neurocognitive impairment in the current era. Rev Med Virol 2012, 22:33-45.
• [30]Clark US, Cohen RA: Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals. Curr Opin Investig Drugs 2010, 11:884-900.
• [31]Schouten EJ, Jahn A, Ben-Smith A, Makombe SD, Harries AD, Aboagye-Nyame F, Chimbwandira F: Antiretroviral drug supply challenges in the era of scaling up ART in Malawi. J Int AIDS Soc 2011, 14(Suppl 1):S4. BioMed Central Full Text
• [32]Blas-Garcia A, Esplugues JV, Apostolova N: Twenty years of HIV-1 non-nucleoside reverse transcriptase inhibitors: time to reevaluate their toxicity. Curr Med Chem 2011, 18:2186-2195.
• [33]Giunta B, Fernandez F, Nikolic WV, Obregon D, Rrapo E, Town T, Tan J: Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflammation 2008, 5:51. BioMed Central Full Text
• [34]Band GP, Ridderinkhof KR, Segalowitz S: Explaining neurocognitive aging: is one factor enough? Brain Cogn 2002, 49:259-267.
• [35]Green AJ, Giovannoni G, Hall-Craggs MA, Thompson EJ, Miller RF: Cerebrospinal fluid tau concentrations in HIV infected patients with suspected neurological disease. Sex Transm Infect 2000, 76:443-446.
• [36]Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, Achim CL: Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. Aids 2005, 19:407-411.
• [37]Brew BJ, Pemberton L, Blennow K, Wallin A, Hagberg L: CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology 2005, 65:1490-1492.
• [38]Alisky JM: The coming problem of HIV-associated Alzheimer's disease. Med Hypotheses 2007, 69:1140-1143.
• [39]Clifford DB, Fagan AM, Holtzman DM, Morris JC, Teshome M, Shah AR, Kauwe JS: CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology 2009, 73:1982-1987.
• [40]Giunta B, Hou H, Zhu Y, Rrapo E, Tian J, Takashi M, Commins D, Singer E, He J, Fernandez F, Tan J: HIV-1 Tat contributes to Alzheimer's disease-like pathology in PSAPP mice. Int J Clin Exp Pathol 2009, 2:433-443.
• [41]Sato-Harada R, Okabe S, Umeyama T, Kanai Y, Hirokawa N: Microtubule-associated proteins regulate microtubule function as the track for intracellular membrane organelle transports. Cell Struct Funct 1996, 21:283-295.
• [42]Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, Johnson A, Blair L, Gordon MN, Dickey CA, Morgan D: LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation 2010, 7:56. BioMed Central Full Text
• [43]Sy M, Kitazawa M, Medeiros R, Whitman L, Cheng D, Lane TE, Laferla FM: Inflammation induced by infection potentiates tau pathological features in transgenic mice. Am J Pathol 2011, 178:2811-2822.
• [44]Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM: Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53:337-351.
• [45]Mookherjee P, Johnson GV: Tau phosphorylation during apoptosis of human SH-SY5Y neuroblastoma cells. Brain Res 2001, 921:31-43.
• [46]Mattson MP: Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 2000, 1:120-129.
• [47]Augustinack JC, Schneider A, Mandelkow EM, Hyman BT: Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 2002, 103:26-35.
• [48]Bancher C, Brunner C, Lassmann H, Budka H, Jellinger K, Wiche G, Seitelberger F, Grundke-Iqbal I, Iqbal K, Wisniewski HM: Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res 1989, 477:90-99.
• [49]Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L: Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
• [50]Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wölfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Götz J: Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010, 142:387-397.
• [51]Braak H, Braak E: Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997, 18:351-357.
• [52]Delacourte A, Sergeant N, Wattez A, Maurage CA, Lebert F, Pasquier F, David JP: Tau aggregation in the hippocampal formation: an ageing or a pathological process? Exp Gerontol 2002, 37:1291-1296.
• [53]Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E: Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995, 26:231-245.
• [54]Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE: Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy. Acta Neuropathol 2006, 111:529-538.
• [55]Patrick C, Crews L, Desplats P, Dumaop W, Rockenstein E, Achim CL, Everall IP, Masliah E: Increased CDK5 expression in HIV encephalitis contributes to neurodegeneration via tau phosphorylation and is reversed with Roscovitine. Am J Pathol 2011, 178:1646-1661.
• [56]Steinbrink F, Evers S, Buerke B, Young P, Arendt G, Koutsilieri E, Reichelt D, Lohmann H, Husstedt IW: Cognitive impairment in HIV infection is associated with MRI and CSF pattern of neurodegeneration. Eur J Neurol 2013, 20:420-428.
• [57]Smith DB, Simmonds P, Bell JE: Brain viral burden, neuroinflammation and neurodegeneration in HAART-treated HIV positive injecting drug users. J Neurovirol 2014, 20:28-38.
• [58]Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, Martin JJ, Cras P: Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993, 61:1828-1834.
• [59]Ramage SN, Anthony IC, Carnie FW, Busuttil A, Robertson R, Bell JE: Hyperphosphorylated tau and amyloid precursor protein deposition is increased in the brains of young drug abusers. Neuropathol Appl Neurobiol 2005, 31:439-448.
• [60]Crews L, Patrick C, Achim CL, Everall IP, Masliah E: Molecular pathology of neuro-AIDS (CNS-HIV). Int J Mol Sci 2009, 10:1045-1063.
• [61]Wang Y, White MG, Akay C, Chodroff RA, Robinson J, Lindl KA, Dichter MA, Qian Y, Mao Z, Kolson DL, Jordan-Sciutto KL: Activation of cyclin-dependent kinase 5 by calpains contributes to human immunodeficiency virus-induced neurotoxicity. J Neurochem 2007, 103:439-455.
• [62]Dewhurst S, Maggirwar SB, Schifitto G, Gendelman HE, Gelbard HA: Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS. J Neuroimmune Pharmacol 2007, 2:93-96.
• [63]Hashimoto M, Sagara Y, Langford D, Everall IP, Mallory M, Everson A, Digicaylioglu M, Masliah E: Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3beta pathway: implications for neuroprotection. J Biol Chem 2002, 277:32985-32991.
• [64]Maggirwar SB, Tong N, Ramirez S, Gelbard HA, Dewhurst S: HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity. J Neurochem 1999, 73:578-586.
• [65]Schifitto G, Zhong J, Gill D, Peterson DR, Gaugh MD, Zhu T, Tivarus M, Cruttenden K, Maggirwar SB, Gendelman HE, Dewhurst S, Gelbard HA: Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol 2009, 15:176-186.
• [66]Augustinack JC, Sanders JL, Tsai LH, Hyman BT: Colocalization and fluorescence resonance energy transfer between cdk5 and AT8 suggests a close association in pre-neurofibrillary tangles and neurofibrillary tangles. J Neuropathol Exp Neurol 2002, 61:557-564.
• [67]Gong CX, Liu F, Grundke-Iqbal I, Iqbal K: Post-translational modifications of tau protein in Alzheimer's disease. J Neural Transm 2005, 112:813-838.
• [68]Plattner F, Angelo M, Giese KP: The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem 2006, 281:25457-25465.
• [69]Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM: Microtubule-associated protein tau: a component of Alzheimer paired helical filaments. J Biol Chem 1986, 261:6084-6089.
• [70]Vincent I, Rosado M, Davies P: Mitotic mechanisms in Alzheimer's disease? J Cell Biol 1996, 132:413-425.
• [71]Schmidt ML, Lee VM, Trojanowski JQ: Relative abundance of tau and neurofilament epitopes in hippocampal neurofibrillary tangles. Am J Pathol 1990, 136:1069-1075.
• [72]Mandelkow EM, Mandelkow E: Tau in Alzheimer's disease. Trends Cell Biol 1998, 8:425-427.
• [73]Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li B, Liu F, Rahman A, Tanimukai H, Grundke-Iqbal I: Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 2005, 1739:198-210.
• [74]Dickson DW, Crystal HA, Mattiace LA, Masur DM, Blau AD, Davies P, Yen SH, Aronson MK: Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 1992, 13:179-189.
• [75]Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, CHARTER Group; HNRC Group: HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011, 17:3-16.
• [76]Sadek JR, Vigil O, Grant I, Heaton RK: The impact of neuropsychological functioning and depressed mood on functional complaints in HIV-1 infection and methamphetamine dependence. J Clin Exp Neuropsychol 2007, 29:266-276.